 |
 |
|
 |
||
 |
 |
|
 |
|
|
Last Updated: 12/15/2008
| Julie Blatt, M.D.
Professor, Fellowship Program Director |  |
Clinical Interests
Late effects of chemotherapy
Experimental therapeutics of solid tumors
Epidemiology of solid tumors
Research Interests
Dr. Blatt's interests fall into three areas of clinical research. The first is in Late Effects of Childhood Cancer Therapy. Past studies have focused on gonadal function, cardiotoxicity and the development of second malignancies. She is a consultant to the Childhood Cancer Survivor Study, a multicenter NIH-funded study which is examining late effects in more than 20,000 survivors of childhood cancer. She also is a past member of the Strategy Group of the Surveillance and End Results Committee of the Children's Oncology Group, which generates late effects study components of therapeutic trials. Current research is focused on neurocognitive deficits in survivors of ALL and inthe development of transition clinics for adolescent-young adult survivors.
Her second clinical research interest is more generically in the epidemiology of pediatric solid tumors. She has collaborated with a number of investigators at the University of North Carolina, including Dr. Andrew Olshan of the Department of Epidemiology, in several studies of neuroblastoma epidemiology, and is studying possible interactions between childhood cancer and autism.
A third interest is in experimental therapeutics of childhood cancer and related diseases. Current studies involve the effects of rapamycin on neuroblastoma.
Recent Accomplishments and Honors
Ad hoc member of NIH study section which has reviewed applications in response to an RFA on cancer survivorship research, reviewer NIH loan repayment program.
Training
Harvard College A.B., mcl 1972
Johns Hopkins Medical School M.D 1976
National Cancer Institute, Pediatric Oncology
Branch, fellowship 1978-82
Board Certifications:
Pediatric Hematology/ Oncology 1982
Pediatrics 1981
Publications
Blatt J, Gula MJ, Orlando SJ, Dickman PS: Indolent course of advanced neuroblastoma in children older than 6 years at diagnosis. Cancer 76:890-894, 1995.
Blatt J, Fitz C, Mirro JR: Increasing identification of central nervous system metastases in children with primary extracranial neuroblastoma. Ped Hematol Oncol 14:233-241, 1997.
Blatt J, Snyderman C, Wollman MR, Mirro J, Janecka IP, Albo VC, Deutsch M, Janosky JE, Wiener ES: Delayed resection in the management of non-orbital rhabdomyosarcoma of the head and neck in childhood. Med Ped Oncol 28:294-98, 1997.
Blatt J, Lee P, Olshan A, Ross JL: Neuroblastoma and related tumors in Turner's syndrome. J Pediatr 1997; 131: 666-670.
Pollack, IF, Dakosso R, Robertson P, Jakacki R, Mirro J Jr, Blatt J, Nicholson S, Packer R, Allen J, Jordan CV: A phase I/II study of high-dose tamoxifen for the treatment of refractory malignant gliomas of childhood. Clin Cancer Res 3:1109-15, 1997.
Blatt J, Hamilton R: Childhood neuroblastoma as a reflection of underlying neuropathologic abnormalities. Cancer 82: 1603-8, 1998.
Maia D, Sciarrotta J, Abindroth K, Blatt J: Sex steroid receptors in Hodgkin's Disease. Leukemia and Lymphoma, 2000; 00:1-7.
Blatt J, Gold SH, Wiley JM, Monahan PE, Cooper HC, Harvey D. Off-label use of recombinant factor VIIa in patients following bone marrow trnasplantation. Bone Marrow Transplantation 2001; 28: 405-7.
Menegaux F, Reitnauer PJ, Cohn SL, Blatt J, Olshan AF. Positive association between congenital anomalies and risk of neuroblastoma. Pediatr Blood Cancer 2005;44:1-7.
Landier W, Bhatia S, Eshelman DA, Forte KJ, Sweeney T, Hester AL, Darling J, Armstrong FD, Blatt J et al.Development of risk-based guidelines for pediatric cancer survivors: The Children's Oncology Group Long-term follow-up guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol 22:4979-90, 2004
Knoll C, Smith RJH, Shores C, Blatt. Lack of genetic predisposition to cisplatin deafness. Laryngoscope 2006;116(1):72-4.
Fu J, Moran C, Blatt J. Response to Rituximab in a Child with Neuroblastoma and Opsoclonus-Myoclonus. Pediatr Blood Cancer 2006 May 1; [Epub ahead of print]); 2008;50: 370-1.
Coulter D, Blatt J, D'Ercole AJ, Moats-Staats B. Inhibition of type 1 insulin-like growth factor rreceptor signaling in Combination with rapamycin or temsirolimus inhibits neuroblastoma cell growth. Anticancer Res 2008;28:1509-16.
Blatt J, Nakayama D. Wilms tumor in association with Hirschsprung disease. J Pediatr Hematol Oncol 2007; 29:858-59.
Wallen K, Perry V, Hadar E, Bouldin T, Loehr J, Blatt J. Posterior fossa tumor and PHACES syndrome: a case report. J Pediatr Hematol Oncol (in press)
Reviews, Chapters, and Editorials (representative)
Blatt J: Annotation: Secondary Leukemias Following Anthracyclines. Pediatric Hematology Oncology 12:111-113, 1995.
Malatack J, Blatt J: Pediatric Hematology/Oncology. In Davis/Zitelli (Eds.): Atlas of Pediatric Physical Diagnosis Gower Medical Pub. 3rd Edition, 1997.
Blatt J. Dexrazoxane and anthracycline cardioprotection. Amer J Oncol Rev 2005; 4:2-4.
Corey SJ, Blatt J: Structure and Function of Hematopoietic Organs. In Zimmerman & Fuhrrnan (Eds.). Pediatric Critical Care Mosby-Year Book, Inc., 3rd Edition, 2006, pp1145-55.
Bhatia S, Blatt J, Meadows AT: Late effects of childhood cancer and its treatment. In Pizzo PS, Poplack DG (eds): Principles and Practice of Pediatric Oncology. J.B. Lipincott Co., 5th Edition, 2006 (in press).
E-mail: jblat@med.unc.edu
Telephone: (919) 966-1178
Address: 1106 POB Chapel Hill, NC 27599-7236
